IN2013MU01177A - - Google Patents

Info

Publication number
IN2013MU01177A
IN2013MU01177A IN1177MU2013A IN2013MU01177A IN 2013MU01177 A IN2013MU01177 A IN 2013MU01177A IN 1177MU2013 A IN1177MU2013 A IN 1177MU2013A IN 2013MU01177 A IN2013MU01177 A IN 2013MU01177A
Authority
IN
India
Prior art keywords
present
tadalafil
stable pharmaceutical
excipienls
particle
Prior art date
Application number
Other languages
English (en)
Inventor
Pavan Kumar M
Jamloki Ashutosh
Bhattacharya Sautik
Sehgel Ashish
Original Assignee
Astron Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astron Res Ltd filed Critical Astron Res Ltd
Priority to PCT/IN2014/000196 priority Critical patent/WO2014167579A2/en
Priority to IN1177MU2013 priority patent/IN2013MU01177A/en
Publication of IN2013MU01177A publication Critical patent/IN2013MU01177A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN1177MU2013 2013-03-28 2014-03-28 IN2013MU01177A (me)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/IN2014/000196 WO2014167579A2 (en) 2013-03-28 2014-03-28 Stable pharmaceutical compositions of tadalafil
IN1177MU2013 IN2013MU01177A (me) 2013-03-28 2014-03-28

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1177MU2013 IN2013MU01177A (me) 2013-03-28 2014-03-28

Publications (1)

Publication Number Publication Date
IN2013MU01177A true IN2013MU01177A (me) 2015-04-17

Family

ID=51690088

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1177MU2013 IN2013MU01177A (me) 2013-03-28 2014-03-28

Country Status (2)

Country Link
IN (1) IN2013MU01177A (me)
WO (1) WO2014167579A2 (me)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016002581A (es) * 2016-02-26 2017-08-25 Apotex Tech Inc Formulaciones farmaceuticas novedosas que comprenden un inhibidor de pde5.
CN113855639B (zh) * 2021-11-04 2023-03-24 昆明源瑞制药有限公司 一种他达拉非片剂及其制备方法
CN115089551B (zh) * 2022-04-07 2024-03-29 江西药都仁和制药有限公司 一种他达拉非片及其制备方法
WO2023232215A1 (en) * 2022-06-02 2023-12-07 Rontis Hellas S.A. Improved pharmaceutical composition containing tadalafil and process for the preparation thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012095151A1 (en) * 2010-12-23 2012-07-19 Zaklady Farmaceutyczne Polpharma Sa Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof
PL2654723T3 (pl) * 2010-12-23 2015-05-29 Zakl Farmaceutyczne Polpharma Sa Stałe postacie leku zawierające tadalafil i sposoby ich otrzymywania
WO2014092661A1 (en) * 2012-01-18 2014-06-19 Mahmut Bilgic Particulate formulations of tadalafil in effervescent form

Also Published As

Publication number Publication date
WO2014167579A3 (en) 2014-12-24
WO2014167579A2 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX2013001677A (es) Formulaciones estables de linaclotida.
SV2016005236A (es) Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina
MY193728A (en) Muscarinic receptor agonists
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
IN2013MU03583A (me)
WO2014137797A3 (en) Stable glucokinase activator compositions
WO2013057741A3 (en) Pharmaceutical compositions of ursodeoxycholic acid
WO2015092810A3 (en) Amorphous form of idelalisib
WO2014068586A3 (en) Solid oral compositions of tolvaptan
MX2016001422A (es) Composicion farmaceutica de fingolimod.
IN2013MU01177A (me)
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
MX359887B (es) Composicion masticable para administracion oral y proceso para preparar la misma.
MX2017008983A (es) Composición farmaceútica de sulfonamida.
NZ712341A (en) A crystalline form of an anxiolytic compound
EA032913B1 (ru) Препараты производных пиримидиндиона
GEP201706672B (en) Dry powder inhaler compositions comprising long acting muscorinic antagonists
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
MX2018003564A (es) 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer.
WO2014122671A3 (en) Solid oral compositions of saxagliptin
MX2019015869A (es) Nuevas formulaciones orales de belinostat.
IN2013CH04314A (me)